Encouraging anti-tumour activity seen across all dose levels and in various tumour indications Clinical benefit rate of 80% ...
JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 ...
44 th Annual J.P. Morgan Healthcare Conference Location: The Westin St. Francis Hotel, San Francisco, CA ...
Biomunex's CSO, Dr. Simon Plyte, is invited to present an oral communication during the 11th Annual Oncology Innovation Forum on the 10th of January 2026 in San Francisco (USA). -- The oral ...
Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 - -- Expects to initiate global Phase 1/2 MAD clinical study ...
Seacrest Foundation to present 2026 Women’s Auxiliary Golden Hearts Luncheon Seacrest Foundation will hold the 2026 Women’s Auxiliary Golden Hearts Luncheon, an uplifting event that brings ...
In absolute terms, 689 accused were convicted in JMFC courts in 2025; compared to 553 in 2024; and 287 in 2023; pointing to ...
Do No Harm alleges Utah Department of Health and Human Services "systematic review" misleads on transgender outcomes.
Phrasing is "anything but objective," former Journal of the American Medical Association deputy editor says. Harvard-led ...
Nearly one-quarter of adults with metabolic dysfunction-associated steatotic liver disease and cirrhosis presented before age ...
The Bank of Nova Scotia ( BNS:CA) RBC Capital Markets Canadian Bank CEO Conference January 6, 2026 12:40 PM EST ...
Background Prehospital delays remain critical barriers to timely acute coronary syndrome (ACS) care, particularly for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback